Biomedical Engineering Reference
In-Depth Information
Treatment
(# pts in
trial/# pts
with marker
analysis)
N (%)
on
treatment
arms
Method
of
KRAS
testing
KRAS
status
Study
mPFS
OS
ORR (%)
CAIRO2
[43]
Cetuximab
+ CAPOX/
bevacizumab
vs. CAPOX/
bevacizumab
(755/520)
Sequencing
and real time
PCR
WT
158 vs. 156
10.5 vs. 10.6 mo
(
21.8 vs. 22.4
mo (
61.4 vs. 50.0
(
P
= 0.30)
P
= 0.64;)
P
= 0.06;)
MT
98 vs. 108
8.1 mo vs. 12.5
mo (
17.2 mo vs.
24.9 (
45.9 vs. 59.2
(
P
= 0.003;)
P
=
P
= 0.03;)
0.03;)
PACCE (interim
analysis
[44])
Panitumumab
+ irinotecan/
bevacizumab
vs. irinotecan/
bevacizumab
(230/200)
Allele
specific real
time PCR
WT
57 vs. 58
NR
NR
47 vs. 54 (HR
= 1.42)
MT
46 vs. 39
NR
NR
30 vs. 38 (HR
= 0.59)
Abbreviations:
CI, confidence interval; EGFR, epidermal growth factor receptor; mAb, monoclonal antibody; mCRC, metastatic colorectal cancer; mo,
months; mPFS, median progression-free survival; MT, mutant; NR, not reported; ORR, overall response rate; OS, overall survival; pts, patients; qPCR,
quantitative polymerase chain reaction; wks, weeks; WT, wild-type.
